Saturday 17 October 2026 Export CNMD’s income statement to Excel — free account

CONMED Corporation

CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 11.6%, free cash flow grew 46.0% and total debt fell 5.40%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.

46.72 0.42 −0.89%

Follow CNMD

Alert me

Market cap: $1.4B
P/E: 25.3×
Fwd P/E: 8.8×
Dividend yield: 0.00%
F-score: 5/9
Altman Z: 1.86
Beneish M: −2.70
Dividend safety: 63/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.16

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.76%

Capital & Financial Ratios $m

Market Cap 1,410.00

Revenue 1,371.66

Net Income 56.50

Free Cash Flow 134.46

Net Debt 796.92

Current Ratio 1.48

Debt/Equity 0.80

P/E ratio 25.25

Fwd P/E 8.83

P/S ratio 1.02

P/B ratio 1.35

Past 5Y EPS Growth 36.38%

This Y EPS Growth (1.18%)

Next Y EPS Growth 5.42%

Next Y revenue growth (0.56%)

Next 5Y EPS Growth 5.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 21.77%

10-year low 10-year high

P/S against its own 10 years 7.59%

10-year low 10-year high

P/B against its own 10 years 7.11%

10-year low 10-year high

EV/Sales against its own 10 years 7.11%

10-year low 10-year high

EV/FCF against its own 10 years 11.17%

10-year low 10-year high

Dividends

Payout Ratio 0.00

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2027	Powerpack
2026	Powerpack
2025	0.60	0.20 0.20 0.20
2024	0.80	0.20 0.20 0.20 0.20
2023	0.80	0.20 0.20 0.20 0.20
2022	0.80	0.20 0.20 0.20 0.20
2021	0.80	0.20 0.20 0.20 0.20
2020	0.80	0.20 0.20 0.20 0.20
2019	0.80	0.20 0.20 0.20 0.20
2018	0.80	0.20 0.20 0.20 0.20
2017	0.80	0.20 0.20 0.20 0.20
2016	0.80	0.20 0.20 0.20 0.20

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	24	24	41	37
Receivables	242	238	248	240
Inventory	318	347	356	360
Other	—	—	—	—
	616	640	673	676

	2023	2024	2025	Q'26
Payables	88	102	94	101
ST’ Debt	1	1	1	177
Other	152	110	139	107
	311	278	315	455

Compound Annual Growth %

	10y	5y	3y
Sales	6.69%	9.77%	9.56%
Cash Flow	12.86%	21.48%	72.31%
Earnings	4.43%	37.66%	0.00%
Book Value	5.85%	7.82%	11.49%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	317	343	—	—	—
’25	321	342	338	373	1,375
’24	312	332	317	346	1,307
’23	295	318	305	327	1,245
’22	242	277	275	251	1,045
’21	233	255	249	274	1,011
’20	214	158	238	253	862

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	13	37	—	—	—
’25	42	29	54	46	171
’24	29	43	51	43	167
’23	(4)	27	46	56	125
’22	0	19	26	(12)	33
’21	22	34	21	34	112
’20	4	6	35	20	65

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	11	34	—	—	—
’25	38	23	48	41	151
’24	27	40	48	39	154
’23	(8)	22	41	52	106
’22	(3)	13	19	(17)	12
’21	19	31	16	31	97
’20	1	2	32	17	52

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.45	0.77	—	—	—
’25	0.19	0.69	0.09	0.54	1.51
’24	0.63	0.96	1.57	1.08	4.25
’23	0.06	0.43	0.50	1.05	2.04
’22	0.47	(5.65)	1.48	0.86	(2.68)
’21	0.31	0.41	0.47	0.75	1.94
’20	0.20	(0.96)	0.23	0.81	0.32

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	35.51	39.74	50.02	60.13	37.66	106.15	71.09	88.01	61.05	38.32	Analyst estimates 2026–2028 Powerpack
	High	50.16	54.77	83.49	116.81	114.96	159.11	155.51	138.47	113.68	74.70
People
People	Employees	3,300	3,100	3,100	3,300	3,400	3,800	4,100	4,000	3,900	3,900
	Revenue/emp, $m	0.23	0.26	0.28	0.29	0.25	0.27	0.25	0.31	0.34	0.35
Income, $m
Income, $m	Revenue	764	796	860	955	862	1,011	1,045	1,245	1,307	1,375
	Gross margin, %	53.48	54.12	54.57	54.94	53.37	56.21	54.64	54.33	56.08	54.59
	EBT	19	29	51	31	2	73	(71)	81	163	71
	EBT margin, %	2.54	3.61	5.89	3.27	0.19	7.23	(6.78)	6.49	12.47	5.17
	Net income	15	55	41	29	10	63	(81)	64	132	47
	Depreciation	55	59	62	84	86	85	74	78	78	80
Per share, $
Per share, $	Revenue	27.46	28.50	30.57	33.72	30.18	34.66	34.80	40.59	42.37	44.29
	Earnings	0.53	1.99	1.45	1.01	0.33	2.14	(2.68)	2.10	4.29	1.52
	Cash flow	1.43	2.35	2.66	3.36	2.26	3.83	1.11	4.09	5.41	5.50
	Capex	(0.53)	(0.46)	(0.59)	(0.71)	(0.46)	(0.51)	(0.73)	(0.62)	(0.42)	(0.64)
	Free cash flow	0.90	1.89	2.07	2.65	1.80	3.32	0.39	3.47	4.99	4.86
	Book value	20.88	22.60	23.55	25.08	24.81	26.93	24.82	27.20	31.21	33.29
	Shares, m	28	28	28	28	29	29	30	31	31	31
Valuation, ×
Valuation, ×	P/E	84.98	25.43	43.97	109.64	339.39	66.24	0.00	52.19	15.95	26.89
	P/S	1.61	1.78	2.10	3.32	3.71	4.09	2.58	2.71	1.62	0.92
	P/B	2.12	2.24	2.73	4.46	4.51	5.26	3.62	4.05	2.19	1.22
	EV/Sales	2.23	2.35	2.61	4.09	4.55	4.75	3.56	3.48	2.29	1.49
	EV/FCF	67.64	35.43	38.57	52.09	76.23	49.51	321.41	40.70	19.45	13.61
Cash, $m
Cash, $m	Operating cash flow	40	66	75	95	65	112	33	125	167	171
	Capex	(15)	(13)	(17)	(20)	(13)	(15)	(22)	(19)	(13)	(20)
	Free cash flow	25	53	58	75	52	97	12	106	154	151
Balance, $m
Balance, $m	Working capital	217	207	213	209	226	263	285	305	362	358
	Total debt	498	486	457	769	754	685	1,055	974	906	835
	Net debt	471	454	439	743	726	664	1,026	950	881	794
	Shareholders’ equity	581	631	662	710	709	785	746	834	963	1,033
Returns, %
Returns, %	ROA	1.21	4.13	3.00	1.82	0.54	3.56	(3.97)	2.80	5.75	2.03
	ROIC	2.24	2.70	4.05	3.40	2.00	4.73	2.47	4.23	6.79	3.51
	ROE	2.52	9.16	6.32	4.17	1.34	8.37	(10.53)	8.16	14.74	4.72

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ESTA Establishment Labs Holdings Inc.	$1.8B	— (loss-making)	— (loss-making)	+31.66% (above 0%: growing)	n/m	+2.75% (above 0%: growing)	70.64%	(6.35%)	Compare
ATEC Alphatec Holdings, Inc.	$1.7B	— (loss-making)	— (loss-making)	+15.07% (above 0%: growing)	n/m	−146.87% (below 0%: shrinking)	72.17%	(0.89%)	Compare
NVCR NovoCure Limited	$1.7B	— (loss-making)	— (loss-making)	+15.60% (above 0%: growing)	n/m	+105.68% (above 0%: growing)	77.61%	(5.75%)	Compare
CNMD CONMED Corporation	$1.4B	25.3×	8.8×	+0.33% (above 0%: growing)	+11.59% (above 0%: growing)	+45.96% (above 0%: growing)	57.49%	10.60%
BVS Bioventus Inc.	$1.2B	16.4×	21.4×	+3.76% (above 0%: growing)	+345.45% (above 0%: growing)	−25.11% (below 0%: shrinking)	68.97%	12.48%	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
Median of peers	$1.2B	—	95.4×	+8.55%	—	−11.18%	69.81%	(3.15%)

All 149 Medical Devices stocks →

CONMED Corporation (CNMD) key facts

Concern: Net income was $47.1 million, or $1.52 per share (basic), a net margin of 3.42%.
Strength: CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024.
CONMED Corporation (CNMD) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, CNMD traded at $46.72, a market capitalization of $1.4 billion.
At that price the stock trades at 25.3× trailing-twelve-month earnings and 1.0× sales; its P/E is higher than 22% of its own readings over the past ten years.
Return on equity was 4.72% and debt-to-equity 0.80.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.86 (grey zone) for fiscal 2025.